Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK1 | Q96PY6 | 6/20 | 0.34 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804959 | 0.85 | NEK1 (0.34) | NEK1UPP1SNCAXDHSLC22A12 | |
| SCHEMBL19631236 | 0.84 | NEK1 (0.37) | NEK1DYRK1A | |
| SCHEMBL1363857 | 0.77 | TRPV4 (0.37) | NEK1DYRK1A | |
| SCHEMBL11661739 | 0.77 | IDO1 (0.39) | NEK1SNCAIDO1DYRK1A | |
| SCHEMBL3602206 | 0.73 | IMPDH2 (0.54) | MAOAMAOB | |
| SCHEMBL31097396 | 0.73 | LRRK2 (0.35) | DYRK1A | |
| SCHEMBL31097398 | 0.73 | LRRK2 (0.35) | DYRK1A | |
| SCHEMBL22122277 | 0.70 | CSNK2A2 (0.37) | NEK1XDHIDO1 | |
| SCHEMBL22122313 | 0.69 | IDO1 (0.33) | NEK1IDO1 | |
| SCHEMBL911722 | 0.69 | NEK1 (0.33) | NEK1ESR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | NEK1 2343/4885UPP1 4720/4885SNCA 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.